Richard Fisher
Directeur Technique/Scientifique/R&D chez Proclara Biosciences, Inc.
Profil
Richard Fisher is currently the Chief Scientific Officer at Proclara Biosciences, Inc. He previously held positions as Director-Molecular Biology, Science & Technology at Biogen MA, Inc., Vice President-Research & Discovery at CytoMed, Inc., Senior VP-Research & Product Development at GlycoFi, Inc., and Vice President-Research & Discovery at UCB Research, Inc. He also served as the Chief Scientific Officer at Intranasal Therapeutics, Inc. Fisher received his undergraduate and doctorate degrees from the University of Iowa.
Postes actifs de Richard Fisher
| Sociétés | Poste | Début |
|---|---|---|
Proclara Biosciences, Inc.
 Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 01/01/2008 |
Anciens postes connus de Richard Fisher
| Sociétés | Poste | Fin |
|---|---|---|
GlycoFi, Inc.
 GlycoFi, Inc. BiotechnologyHealth Technology GlycoFi, Inc. develops biopharmaceutical products. It provides protein production technology to develop, produce and commercialize biotherapeutics products. The company was founded by Tillman Gerngross in 2000 and is headquartered in Lebanon, NH. | Directeur Technique/Scientifique/R&D | 01/01/2006 |
UCB Research, Inc.
 UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 01/01/2005 |
CytoMed, Inc.
 CytoMed, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., CytoMed, Inc. is a company that develops therapeutics for cancer treatment. The company is based in Cambridge, MA. CytoMed was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on February 12, 1999 for $19.29 million. | Directeur Technique/Scientifique/R&D | 02/01/1998 |
| Intranasal Therapeutics, Inc. | Directeur Technique/Scientifique/R&D | - |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | - |
Formation de Richard Fisher
| University of Iowa | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Health Technology |
CytoMed, Inc.
CytoMed, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., CytoMed, Inc. is a company that develops therapeutics for cancer treatment. The company is based in Cambridge, MA. CytoMed was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on February 12, 1999 for $19.29 million. | Health Technology |
GlycoFi, Inc.
GlycoFi, Inc. BiotechnologyHealth Technology GlycoFi, Inc. develops biopharmaceutical products. It provides protein production technology to develop, produce and commercialize biotherapeutics products. The company was founded by Tillman Gerngross in 2000 and is headquartered in Lebanon, NH. | Health Technology |
UCB Research, Inc.
UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Commercial Services |
| Intranasal Therapeutics, Inc. |